Cytokinetics (NASDAQ:CYTK) Shares Purchased by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased $1,001–$15,000 of Cytokinetics shares on September 29, alongside purchases of several other healthcare and consumer stocks.
• Cytokinetics shares opened at $61.62, down 1.9%, and remain well below their 12-month high of $88.31. The company beat quarterly EPS and revenue expectations, but revenue declined 57.1% year over year.
• Additional Phase 3 data for aficamten strengthened the potential outlook for Cytokinetics’ hypertrophic cardiomyopathy treatment, while analysts maintained a generally positive view with a “Moderate Buy” consensus and $106.06 average price target; insiders have sold $13.6 million of stock over the past 90 days.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Cytokinetics, Incorporated (NASDAQ:CYTK). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Cytokinetics stock on September 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Alkermes NASDAQ: ALKS on 9/29/2026.

Cytokinetics Trading Down 1.9%

Shares of Cytokinetics stock opened at $61.62 on Wednesday. Cytokinetics, Incorporated has a 12 month low of $54.30 and a 12 month high of $88.31. The firm has a market cap of $7.67 billion, a P/E ratio of -8.53 and a beta of 0.41. The stock's fifty day moving average price is $71.13 and its 200-day moving average price is $73.27.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.13. The business had revenue of $28.62 million for the quarter, compared to analysts' expectations of $17.59 million. During the same quarter in the prior year, the company posted ($1.12) EPS. The business's revenue for the quarter was down 57.1% on a year-over-year basis. Analysts forecast that Cytokinetics, Incorporated will post -5.98 earnings per share for the current year.

Insider Transactions at Cytokinetics

In related news, CEO Robert Blum sold 7,500 shares of the firm's stock in a transaction on Monday, October 12th. The stock was sold at an average price of $62.88, for a total transaction of $471,600.00. Following the sale, the chief executive officer owned 278,544 shares of the company's stock, valued at approximately $17,514,846.72. This trade represents a 2.62% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B. Parshall sold 5,000 shares of the business's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total value of $357,400.00. Following the completion of the transaction, the director directly owned 10,784 shares of the company's stock, valued at approximately $770,840.32. The trade was a 31.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 191,426 shares of company stock valued at $13,601,885 over the last 90 days. Company insiders own 2.60% of the company's stock.

Institutional Investors Weigh In On Cytokinetics

Several hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. raised its position in shares of Cytokinetics by 11.9% in the 1st quarter. Principal Financial Group Inc. now owns 1,093,485 shares of the biopharmaceutical company's stock valued at $72,072,000 after purchasing an additional 116,593 shares in the last quarter. Frazier Life Sciences Management L.P. increased its position in shares of Cytokinetics by 5.0% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 934,642 shares of the biopharmaceutical company's stock worth $59,387,000 after acquiring an additional 44,197 shares in the last quarter. ADAR1 Capital Management LLC lifted its holdings in shares of Cytokinetics by 17.1% in the first quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company's stock valued at $41,692,000 after purchasing an additional 92,390 shares in the last quarter. Siren L.L.C. acquired a new stake in Cytokinetics during the 1st quarter worth about $40,466,000. Finally, Handelsbanken Fonder AB lifted its position in Cytokinetics by 63.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company's stock worth $34,502,000 after buying an additional 157,700 shares in the last quarter.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Additional analyses from the Phase 3 ACACIA-HCM study further characterized aficamten’s effects across exercise-performance measures and patient responder groups. The data also supported the drug’s dose-adjustment approach and safety profile, potentially strengthening Cytokinetics’ case for aficamten as a future treatment for non-obstructive HCM. Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
• Positive Sentiment: Several market commentaries highlighted the Phase 3 aficamten results and the possibility that the drug’s multi-domain benefits could improve Cytokinetics’ long-term commercial outlook. The company’s pipeline and potential heart-drug opportunity are driving the fresh investor interest, although regulatory and commercialization risks remain. Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten in NHCM
• Neutral Sentiment: Wall Street Zen upgraded Cytokinetics to a “Hold,” suggesting a more balanced view of the shares after the recent clinical updates rather than a clearly bullish or bearish shift. Wall Street Zen Upgrades Cytokinetics to Hold
• Neutral Sentiment: Chief Executive Officer Robert I. Blum sold 7,500 shares for approximately $471,600 under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance and he retained 278,544 shares, it is a limited signal of insider sentiment, though it may add modest pressure to investor perception. SEC Form 4 Filing

Analysts Set New Price Targets

A number of brokerages recently weighed in on CYTK. HC Wainwright reaffirmed a "buy" rating and issued a $140.00 price target on shares of Cytokinetics in a research note on Monday, August 31st. Morgan Stanley upgraded Cytokinetics from an "overweight" rating to a "buy" rating in a research report on Tuesday, September 1st. UBS Group raised shares of Cytokinetics from a "neutral" rating to a "buy" rating and boosted their price target for the company from $69.00 to $115.00 in a research note on Monday, June 29th. Citizens Jmp lifted their price objective on shares of Cytokinetics from $105.00 to $110.00 and gave the company a "market outperform" rating in a report on Friday, August 7th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cytokinetics in a research report on Friday, July 17th. Eighteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $106.06.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.